Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Gains from Investment Securities: 2014-2025

Historic Gains from Investment Securities for ImmunityBio (IBRX) over the last 10 years, with Sep 2025 value amounting to -$14.9 million.

  • ImmunityBio's Gains from Investment Securities rose 52.42% to -$14.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$27.3 million, marking a year-over-year decrease of 138.35%. This contributed to the annual value of -$20.0 million for FY2024, which is 141.92% down from last year.
  • ImmunityBio's Gains from Investment Securities amounted to -$14.9 million in Q3 2025, which was down 283.26% from -$3.9 million recorded in Q2 2025.
  • Over the past 5 years, ImmunityBio's Gains from Investment Securities peaked at $79.4 million during Q4 2023, and registered a low of -$31.3 million during Q3 2024.
  • In the last 3 years, ImmunityBio's Gains from Investment Securities had a median value of -$3.9 million in 2025 and averaged $1.1 million.
  • Within the past 5 years, the most significant YoY rise in ImmunityBio's Gains from Investment Securities was 7,753.61% (2023), while the steepest drop was 3,124.59% (2023).
  • Over the past 5 years, ImmunityBio's Gains from Investment Securities (Quarterly) stood at $3.6 million in 2021, then tumbled by 71.98% to $1.0 million in 2022, then surged by 7,753.61% to $79.4 million in 2023, then crashed by 112.26% to -$9.7 million in 2024, then soared by 52.42% to -$14.9 million in 2025.
  • Its Gains from Investment Securities was -$14.9 million in Q3 2025, compared to -$3.9 million in Q2 2025 and $1.2 million in Q1 2025.